↓ Skip to main content

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison

Overview of attention for article published in BMC Psychiatry, December 2014
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
Published in
BMC Psychiatry, December 2014
DOI 10.1186/s12888-014-0298-4
Pubmed ID
Authors

Tatiana Dilla, Jörgen Möller, Paul O’Donohoe, María Álvarez, José A Sacristán, Michael Happich, Antje Tockhorn

Abstract

BackgroundIn schizophrenia, medication adherence is critical to achieve better patient outcomes and to avoid relapses, which are responsible for a significant proportion of total healthcare costs for this chronic illness. The aim of this study was to assess the cost-effectiveness of olanzapine long-acting injection (OLAI) compared with risperidone long-acting injection (RLAI) in patients with schizophrenia in Spain.MethodsA discrete event simulation (DES) model was developed from a Spanish healthcare system perspective to estimate clinical and economic outcomes for patients with schizophrenia over a five-year period. Patients who had earlier responded to oral medication and have a history of relapse due to adherence problems were considered. Identical model populations were treated with either OLAI or RLAI. In the absence of a head-to-head clinical trial, discontinuation and relapse rates were obtained from open-label studies. The model accounted for age, gender, risks of relapse and discontinuation, relapse management, hospitalization, treatment switching and adverse events. Direct medical costs for the year 2011 and outcomes including relapse avoided, life years (LYs), and quality-adjusted life years (QALYs) were discounted at a rate of 3%.ResultsWhen comparing RLAI and OLAI, the model predicts that OLAI would decrease 5-year costs by ¿2,940 (Standard Deviation between replications 300.83), and result in a QALY and LY gains of 0.07 (SD 0.019) and 0.04 (SD 0.025), respectively. Patients on OLAI had fewer relapses compared to RLAI (1.392 [SD 0.035] vs. 1.815 [SD 0.035]) and fewer discontinuations (1.222 [SD 0.031] vs. 1.710 [SD 0.039]). Sensitivity analysis indicated that the study was robust and conclusions were largely unaffected by changes in a wide range of parameters.ConclusionsThe present evaluation results in OLAI being dominant over RLAI, meaning that OLAI represents a more effective and less costly alternative compared to RLAI in the treatment of patients with schizophrenia in the Spanish setting.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Italy 1 1%
Unknown 67 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 20%
Other 10 14%
Student > Master 9 13%
Student > Ph. D. Student 5 7%
Student > Doctoral Student 4 6%
Other 13 19%
Unknown 14 20%
Readers by discipline Count As %
Medicine and Dentistry 15 22%
Pharmacology, Toxicology and Pharmaceutical Science 10 14%
Psychology 7 10%
Economics, Econometrics and Finance 3 4%
Nursing and Health Professions 3 4%
Other 10 14%
Unknown 21 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2015.
All research outputs
#11,519,351
of 14,535,828 outputs
Outputs from BMC Psychiatry
#2,721
of 3,390 outputs
Outputs of similar age
#203,360
of 302,230 outputs
Outputs of similar age from BMC Psychiatry
#303
of 364 outputs
Altmetric has tracked 14,535,828 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,390 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 302,230 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 364 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.